Suppression of sustained ventricular tachyarrhythmias: A comparison of d,l-sotalol with no antiarrhythmic drug treatment

Journal of the American College of Cardiology

Volumn 33, Issue 1, 1999, Pages 46-52

  Kühlkamp, Volker ^a   Mewis, Christian ^a   Mermi, Johannes ^a   Bosch, Ralph F ^a   Seipel, Ludger ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; METOPROLOL; SOTALOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DRUG EFFICACY; FEMALE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADMINISTRATION, ORAL; AGED; ANTI-ARRHYTHMIA AGENTS; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOTALOL; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 0032921463     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00521-X     Document Type: Article

References (43)

1. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular action potentials and other pharmacologic actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970;39:675-87.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 1989;321:406-12.
3. The Cardiac Arrhythmia Suppression Trial II (CAST II) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New Engl J Med 1992;327:227-33.
4. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. New Engl J Med 1993;329:452-8.
5. Singh BN. Expanding indications for the use of class III agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 1995;6:887-900.
6. Senges J, Lengfelder W, Jauering R, et al. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Circulation 1984;69:577-84.
7. Steinbeck G, Bach P, Haberl R. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol 1986;8:949-58.
8. Nademanee K, Feld G, Hendrickson J, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72:555-64.
9. Roden DM. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol 1993;72:51a-5.
10. Kehoe RF, Zheutlin TA, Dunnington CS, Mattioni TA, Yu G, Spangenberg RB. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am Heart J 1990;65:58A-64.
11. Kehoe RF, McNeil DJ, Zheutlin TA, et al. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. Am J Cardiol 1993;72:56A-66.
12. Singh BN. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Am J Cardiol 1993;72 Suppl:114F-124F.
13. Wilber DJ, Garan H, Finkelstein DM, et al. Out-of-hospital cardiac arrest-use of electrophysiologic testing in the prediction of long-term outcome. New Engl J Med 1988;318:19-24.
14. Trappe HJ, Brugada P, Talajic M, et al. Prognosis of patients with ventricular tachycardia and ventricular fibrillation: role of the underlying etiology. J Am Coll Cardiol 1988;12:166-74.
15. Böcker D, Block M, Isbruch F, et al. Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial versus nonthoracotomy lead systems. Am J Cardiol 1993;71:1064-8.
16. Hii JTY, Gillis AM, Wyse DG, Sheldon RS, Duff HJ, Mitchell LB. Risks of developing supraventricular and ventricular tachyarrhythmias after implantation of a cardioverter-defibrillator, and timing the activation of arrhythmia termination therapies. Am J Cardiol 1993;71:565-8.
17. Greene HL, Richardson DW, Barker AH, et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (The Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:1-6.
18. Levine JH, Mellits D, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558-66.
19. Anderson JL, Karagounis LA, Roskelley M, Osborn JS, Handrahan D. Effect of prophylactic antiarrhythmic therapy on time to implantable cardioverter-defibrillator discharge in patients with ventricular tachyarrhythmias. Am J Cardiol 1994;73:683-7.
20. Brugada P, Wellens HJJ. Need and design of a prospective study to assess the value of different strategic approaches for management of ventricular tachycardia or fibrillation. Am J Cardiol 1986;57:1180-4.
21. Brugada P, Lemery R, Talajic M, Della Bella P, Wellens HJJ. Treatment of patients with ventricular tachycardia or ventricular fibrillation: First lessons from the "Parallel Study". In: Brugada P, Wellens HJJ, editors. Cardiac Arrhythmias: Where to Go from Here? New York: Futura 1987:457-70.
22. Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone, clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New Engl J Med 1981;305:539-45.
23. Waxman HL, Groh WC, Marchlinski FE, et al. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients. Am J Cardiol 1982;50:1066-74.
24. Hamer AW, Finerman WB, Peter T, Mandel WJ. Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 1981;102:992-1000.
25. CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-7.
26. Kim SG, Felder SD, Figura I, Johnston DR, Wasper LE, Fisher JD. Comparison of programmed stimulation and holter monitoring for predicting long-term efficacy and inefficacy of amiodarone used alone or in combination with a class 1A antiarrhythmic agent in patients with ventricular tachycardia. J Am Coll Cardiol 1987;9:398-404.
27. Lee RJ, Wong M, Namekawawong M, et al. Long term results of electrophysiologically guided sotalol therapy for life threatening ventricular arrhythmias. Am Heart J 1996;132:973-8.
28. Leclercq J-F, Leenhardt A, Lemarec H, et al. Predictive value of electrophysiologic studies during treatment of ventricular tachycardia with the beta-blocking agent nadolol. J Am Coll Cardiol 1990;16:413-7.
29. Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA. Clinical experience with sotalol in patients with drug refractory ventricular arrhythmias. J Am Coll Cardiol 1989;13:145-52.
30. Kuchar DL, Garan H, Venditti FJ, et al. Usefulness of sotalol in supressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. Am Heart J 1989;64:33-6.
31. Gonzalez R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 1988;12:1568-72.
32. Kus T, Campa MA, Nadeau R, Dubuc M, Kaltenbrunner W, Shenasa M. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. Am Heart J 1992;123:82-9.
33. Kudenchuk PJ, Kron J, Walance CG, Cutler JE, Griffith KK, McAnulty JH. Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease. Am J Cardiol 1990;66:725-30.
34. Volgman AS, Zheutlin TA, Mattioni TA, Parker MA, Kehoe RF. Reproducibility of programmed electrical stimulation responses in patients with ventricular tachycardia or fibrillation associated with coronary artery disease. Am J Cardiol 1992;70:758-63.
35. Wellens HJJ, Bär FWHM, Düren DR, Dohmen HJ. Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia. Am J Cardiol 1977;40:579-85.
36. Patterson E, Scherlag BJ, Lazzara R. Mechanism of prevention of sudden death by nadolol: differential actions on arrhythmia triggers and substrate after myocardial infarction in the dog. J Am Coll Cardiol 1986;8:1365-72.
37. Schwartz PJ, Motolese M, Pollavini G, et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol 1992;3:2-16.
38. Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-1202.
39. Tomoike H, Ross J, Franklin D, Crozatier B, McKown D, Kemper WS. Improvement by propranolol of regional myocardial dysfunction and abnormal coronary flow pattern in conscious dogs with coronary narrowing. Am J Cardiol 1978;41:689-96.
40. Mewis C, Kühlkamp V, Mermi J, Seipel L. Inducibility of ventricular tachyarrhythmias during long-term sotalol therapy in asymptomatic patients [Abstract]. Eur Heart J 1996;17:389.
41. Wever EFD, Hauer RNW, van Capelle FJL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-203.
42. Böcker D, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G. Comparison of d,l-Sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996;94:151-7.
43. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. New Engl J Med 1997;337:1576-83.